The group’s principle activity is to provide molecular diagnostic services focusing on the development and commercialization of in vitro diagnostic tests for cancer screening and cancer specialty applications including monitoring and classification. The group also provides Biomarker services including Biomarker Discovery, and Biomarker Selection based on its leading DNA methylation technology portfolio. The group operates from United States.
